A Novel Process for Developing Fully Human Monoclonal Antibodies - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

A Novel Process for Developing Fully Human Monoclonal Antibodies
The authors describe a process for generating high affinity, fully human antibodies in culture. Specially selected splenocytes are incubated with cytokines and low levels of antigen, yielding affinity-matured, class-switched B cells. The fully human, specific antibodies produced by these cells can then be cloned and expressed for further characterization.

Pharmaceutical Technology
pp. s28-s31

14. A. Schedl et al., Nucleic Acids Res. 20, 3073–3077 (1992).

15. A. Schedl et al., Nucleic Acids Res. 21, 4783–4787 (1993).

16. A. Schedl et al., Nature 362, 258–261 (1993).

17. L. M. Weiner, J. Immunother. 29, 1–9 (2006).

18. R. Jefferis, Adv. Exp. Med. Biol. 564, 143–148 (2005).

19. R. Jefferis and J. Lund, Chem. Immunol. 65, 111–128 (1997).

20. M. A. Coccia and P. Brams, J. Immunol. 161, 5772–5780 (1998).

21. S. M. Santini et al., J. Exp. Med. 191, 1777–1788 (2000).

22. J. M. Carballido et al., Nat. Med. 6, 103–106 (2000).

23. R. Carlsson et al., J. Immunol. 148, 1065–1071 (1992).

24. C. Lapenta et al., J. Exp. Med. 198, 361–367 (2003).

25. M. Tary-Lehmann, A. Saxon, and P. V. Lehmann, Immunol. Today 16, 529–533 (1995).

26. A. R. T. Gerritsen et al., High Throughput Bio-Layer Interferometry in Therapeutic Antibody Discovery and Development (ForteBio, 2010), http://www.fortebio.com/documents/Genmab_Screening_Europe_2010.pdf, accessed Oct. 2012.

27. Octet Biosensors Product Insert, "Streptavidin High Binding Capacity Biosensors-Kinetics and Screening Grade," (ForteBio, 2007), http://www.fortebio.com/documents/41-0046-PD_Rev_B_Streptavidin_High_Binding_PI.pdf, accessed Oct. 2012.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology,
Click here